AR056346A1 - Compuestos y composiciones como inhibidores de quinasa de proteina - Google Patents
Compuestos y composiciones como inhibidores de quinasa de proteinaInfo
- Publication number
- AR056346A1 AR056346A1 ARP060101900A ARP060101900A AR056346A1 AR 056346 A1 AR056346 A1 AR 056346A1 AR P060101900 A ARP060101900 A AR P060101900A AR P060101900 A ARP060101900 A AR P060101900A AR 056346 A1 AR056346 A1 AR 056346A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- 4alkyl
- hetero
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos, composiciones farmacéuticas que comprenden a estos compuestos, y uso de los compuestos para preparar un medicamento. Los compuesto son utiles para prevenir o tratar las enfermedades o los trastornos asociados con una actividad de quinasa anormal o mal regulada, en particular las enfermedades o los trastornos que involucren una activacion anormal de las quinasas Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKKalfa, IKKbeta, JNK1alfa1, JNK2alfa2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFRalfa, PKA, PKCalfa, PKD2, ROCK-II, Ros, Rsk1, SAPK2alfa, SAPK2beta, SAPK3, SAPK4, SGK, Syk, Tie2 y TrkB. Estas enfermedades incluyen trastornos proliferativos y enfermedades de una activacion inadecuada de los sistemas inmune y nervioso. Reivindicacion 1: Un compuesto seleccionado a partir de la formula (1), n se selecciona a partir de 0, 1 y 2; m se selecciona a partir de 0, 1 y 2; Y1 se selecciona a partir de N y CR5; en donde R5 se selecciona a partir de hidrogeno y alquilo C1-6; Y2 se selecciona a partir de O y S; R1 se selecciona a partir de hidrogeno y alquilo C1-6; R2 se selecciona a partir de hidrogeno y alquilo C1-6; R3 se selecciona a partir de hidrogeno, halogeno, hidroxilo, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; R4 se selecciona a partir de-NR5C(O)R6 y -C(O)NR5R6; en donde R5 se selecciona a partir de hidrogeno y alquilo C1-6; en donde R6 se selecciona a partir de ariloC6-10-alquiloC0-4, heteroariloC5-10-alquiloC0-4, ciclo-alquiloC3-10-alquiloC0-4, y hetero-cicloalquiloC3-10-alquiloC0-4; en donde cualquier arilo, hetero-arilo, ciclo-alquilo, o hetero-ciclo-alquilo, o hetero-ciclo-alquilo de R6 está opcionalmente sustituido con 1 a 3 radicales seleccionados a partir de halogeno, hidroxilo, -NR5R5, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido por halogeno, hetero-ariloC5-10-alquiloC1-4, heterocicloC3-8-alquiloC0-4 y heterocicloC3-8-alcoxiloC0-4; en donde cualquier sustituyente de hetero-arilo o hetero-ciclo-alquilo R6 está opcionalmente sustituido por 1 a 3 radicales independientemente seleccionados a partir de alquilo C1-6 e hidroxilo-alquiloC1-6; R7 se selecciona a partir de hidrogeno, halogeno, hidroxilo, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido halogeno, ariloC6-10-alquiloC0-4, hetero-ariloC5-10-alquiloC0-4, cicloalquiloC3-10-alquiloC0-4, y hetero-ciclo-alquiloC3-10-alquiloC0-4; y las sales farmacéuticamente aceptables, hidratos, solvatos, e isomeros del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68068405P | 2005-05-13 | 2005-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056346A1 true AR056346A1 (es) | 2007-10-03 |
Family
ID=37074687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101900A AR056346A1 (es) | 2005-05-13 | 2006-05-11 | Compuestos y composiciones como inhibidores de quinasa de proteina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8183248B2 (es) |
| EP (1) | EP1891066B1 (es) |
| JP (1) | JP5016593B2 (es) |
| KR (1) | KR20080025039A (es) |
| CN (1) | CN101175753B (es) |
| AR (1) | AR056346A1 (es) |
| AT (1) | ATE492545T1 (es) |
| AU (1) | AU2006247757B2 (es) |
| BR (1) | BRPI0610278A2 (es) |
| CA (1) | CA2607299C (es) |
| DE (1) | DE602006019088D1 (es) |
| ES (1) | ES2358344T3 (es) |
| GT (1) | GT200600197A (es) |
| MX (1) | MX2007014066A (es) |
| PE (1) | PE20061366A1 (es) |
| PL (1) | PL1891066T3 (es) |
| RU (1) | RU2411242C2 (es) |
| TW (1) | TW200726766A (es) |
| WO (1) | WO2006124462A2 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008120850A (ru) | 2005-10-28 | 2009-12-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве ингибиторов протеинкиназ |
| EP2532235A1 (en) | 2006-09-22 | 2012-12-12 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| CA2681756C (en) * | 2007-03-28 | 2015-02-24 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| PE20091561A1 (es) * | 2008-02-29 | 2009-10-30 | Array Biopharma Inc | Compuestos inhibidores de raf y metodos para su uso |
| AU2009222144A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine Raf inhibitors |
| US20110003809A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| CA2716949A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| EP2300013B1 (en) | 2008-05-21 | 2017-09-06 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| MX2011000661A (es) | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
| US20120329826A1 (en) * | 2010-03-03 | 2012-12-27 | OSI Pharmaceuticals,. LLC | Substituted-5-aminopyrrolo/pyrazolopyridines |
| CA3240281A1 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| JP5999177B2 (ja) | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| KR20140058543A (ko) | 2011-07-08 | 2014-05-14 | 노파르티스 아게 | 신규 피롤로 피리미딘 유도체 |
| EP2731612A4 (en) | 2011-07-13 | 2015-04-08 | Pharmacyclics Inc | BRUTON TYROSINE KINASE HEMMER |
| CN103073508B (zh) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| US9782406B2 (en) | 2011-10-25 | 2017-10-10 | Peking University Shenzhen Graduate School | Kinase inhibitor and method for treatment of related diseases |
| JP2015504876A (ja) * | 2011-12-22 | 2015-02-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン／トレオニンキナーゼ阻害剤としての２，４−ジアミン−ピリミジン誘導体 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| CN104736178A (zh) | 2012-06-04 | 2015-06-24 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| SG11201503842PA (en) | 2012-11-15 | 2015-06-29 | Pharmacyclics Inc | Pyrrolopyrimidine compounds as kinase inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN109776525B (zh) | 2013-04-19 | 2022-01-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
| TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
| CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
| EP3052486A1 (en) | 2013-09-30 | 2016-08-10 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CA2942528A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| MX2017001671A (es) | 2014-08-07 | 2017-07-04 | Pharmacyclics Llc | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| CN105801584B (zh) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| CN109374896A (zh) * | 2018-11-22 | 2019-02-22 | 中山大学孙逸仙纪念医院 | Plk3前列腺癌预后诊断检测试剂及其试剂盒 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50087B (sr) | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EA006227B1 (ru) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| CA2412560C (en) | 2000-06-26 | 2008-12-30 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
| JP2007502776A (ja) * | 2003-08-15 | 2007-02-15 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｒｔｋ阻害剤としての６−置換アニリノプリン類 |
| US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
-
2006
- 2006-05-10 CN CN2006800161327A patent/CN101175753B/zh not_active Expired - Fee Related
- 2006-05-10 MX MX2007014066A patent/MX2007014066A/es active IP Right Grant
- 2006-05-10 EP EP06752481A patent/EP1891066B1/en not_active Not-in-force
- 2006-05-10 PL PL06752481T patent/PL1891066T3/pl unknown
- 2006-05-10 US US11/914,308 patent/US8183248B2/en not_active Expired - Fee Related
- 2006-05-10 WO PCT/US2006/018096 patent/WO2006124462A2/en active Application Filing
- 2006-05-10 AU AU2006247757A patent/AU2006247757B2/en not_active Ceased
- 2006-05-10 GT GT200600197A patent/GT200600197A/es unknown
- 2006-05-10 RU RU2007145935/04A patent/RU2411242C2/ru not_active IP Right Cessation
- 2006-05-10 CA CA2607299A patent/CA2607299C/en not_active Expired - Fee Related
- 2006-05-10 KR KR1020077026230A patent/KR20080025039A/ko not_active Application Discontinuation
- 2006-05-10 BR BRPI0610278-6A patent/BRPI0610278A2/pt not_active IP Right Cessation
- 2006-05-10 ES ES06752481T patent/ES2358344T3/es active Active
- 2006-05-10 AT AT06752481T patent/ATE492545T1/de active
- 2006-05-10 DE DE602006019088T patent/DE602006019088D1/de active Active
- 2006-05-10 JP JP2008511323A patent/JP5016593B2/ja not_active Expired - Fee Related
- 2006-05-11 PE PE2006000501A patent/PE20061366A1/es not_active Application Discontinuation
- 2006-05-11 AR ARP060101900A patent/AR056346A1/es unknown
- 2006-05-12 TW TW095116981A patent/TW200726766A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1891066T3 (pl) | 2011-05-31 |
| GT200600197A (es) | 2007-03-28 |
| CA2607299C (en) | 2013-05-07 |
| EP1891066B1 (en) | 2010-12-22 |
| ES2358344T3 (es) | 2011-05-09 |
| WO2006124462A3 (en) | 2007-01-04 |
| CN101175753B (zh) | 2011-03-23 |
| PE20061366A1 (es) | 2007-01-05 |
| JP5016593B2 (ja) | 2012-09-05 |
| RU2007145935A (ru) | 2009-06-20 |
| ATE492545T1 (de) | 2011-01-15 |
| US8183248B2 (en) | 2012-05-22 |
| JP2008540556A (ja) | 2008-11-20 |
| CN101175753A (zh) | 2008-05-07 |
| AU2006247757B2 (en) | 2009-08-27 |
| AU2006247757A1 (en) | 2006-11-23 |
| BRPI0610278A2 (pt) | 2010-06-08 |
| CA2607299A1 (en) | 2006-11-23 |
| MX2007014066A (es) | 2008-02-11 |
| US20090118273A1 (en) | 2009-05-07 |
| DE602006019088D1 (de) | 2011-02-03 |
| WO2006124462A2 (en) | 2006-11-23 |
| EP1891066A2 (en) | 2008-02-27 |
| RU2411242C2 (ru) | 2011-02-10 |
| KR20080025039A (ko) | 2008-03-19 |
| TW200726766A (en) | 2007-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056346A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| ATE444294T1 (de) | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren | |
| AR063343A1 (es) | Compuestos para modular c-kit y receptores de pdgfr | |
| NO20072887L (no) | Forbindelser og sammensetninger som protein kinase inhibitorer | |
| CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| ATE482958T1 (de) | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren | |
| PE20110223A1 (es) | DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA | |
| EA200901654A1 (ru) | Ингибиторы и способы с их использованием | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| AR049511A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
| ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
| EA201000003A1 (ru) | Ингибиторы протеинкиназ и способы их применения | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| UY31821A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| GT200600394A (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis. | |
| ECSP077994A (es) | Aminopirimidinas como moduladores de cinasa | |
| BRPI0511907A (pt) | novos derivados de fenilpiperidinas/piperizinas dissubstituìdos como moduladores da neurotransmissão de dopamina | |
| BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
| NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
| ECSP077991A (es) | Aminopirimidinas como moduladores de cinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |